Norinchukin Bank The Has $20.52 Million Position in Zoetis Inc (ZTS)

Norinchukin Bank The boosted its holdings in Zoetis Inc (NYSE:ZTS) by 16.3% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 224,162 shares of the company’s stock after acquiring an additional 31,339 shares during the quarter. Norinchukin Bank The’s holdings in Zoetis were worth $20,524,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Signature Estate & Investment Advisors LLC bought a new position in Zoetis in the 3rd quarter worth about $112,000. Sun Life Financial INC increased its stake in Zoetis by 604.3% in the 2nd quarter. Sun Life Financial INC now owns 1,310 shares of the company’s stock worth $112,000 after acquiring an additional 1,124 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. increased its stake in Zoetis by 3,033.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 1,410 shares of the company’s stock worth $120,000 after acquiring an additional 1,365 shares during the last quarter. Fort L.P. bought a new position in Zoetis in the 2nd quarter worth about $121,000. Finally, Harvest Fund Management Co. Ltd bought a new position in Zoetis in the 3rd quarter worth about $146,000. Institutional investors and hedge funds own 89.29% of the company’s stock.

ZTS has been the topic of a number of research analyst reports. JPMorgan Chase & Co. upgraded Zoetis from a “neutral” rating to an “overweight” rating and set a $100.00 target price on the stock in a research note on Monday, October 15th. Cantor Fitzgerald restated a “buy” rating and issued a $98.00 target price on shares of Zoetis in a research note on Monday, October 1st. Stifel Nicolaus lowered Zoetis from a “buy” rating to a “hold” rating and set a $95.00 target price on the stock. in a research note on Tuesday, August 21st. They noted that the move was a valuation call. Zacks Investment Research upgraded Zoetis from a “hold” rating to a “buy” rating and set a $101.00 target price on the stock in a research note on Monday, September 10th. Finally, Morgan Stanley set a $100.00 target price on Zoetis and gave the stock a “hold” rating in a research note on Friday, November 2nd. Seven research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Zoetis presently has a consensus rating of “Buy” and a consensus target price of $94.00.

In other news, insider Roxanne Lagano sold 2,000 shares of the company’s stock in a transaction dated Monday, October 1st. The stock was sold at an average price of $92.03, for a total value of $184,060.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Kristin C. Peck sold 11,500 shares of the stock in a transaction dated Monday, November 12th. The shares were sold at an average price of $94.78, for a total value of $1,089,970.00. The disclosure for this sale can be found here. Insiders sold a total of 180,191 shares of company stock valued at $17,057,785 over the last quarter. Company insiders own 0.35% of the company’s stock.

ZTS opened at $92.48 on Thursday. Zoetis Inc has a 12-month low of $69.35 and a 12-month high of $96.57. The company has a debt-to-equity ratio of 3.04, a current ratio of 4.06 and a quick ratio of 2.63. The stock has a market capitalization of $45.37 billion, a PE ratio of 38.53, a PEG ratio of 1.86 and a beta of 0.97.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, November 1st. The company reported $0.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.77 by $0.06. Zoetis had a return on equity of 75.51% and a net margin of 20.35%. The firm had revenue of $1.48 billion during the quarter, compared to analysts’ expectations of $1.46 billion. During the same period in the prior year, the business earned $0.65 EPS. The company’s revenue for the quarter was up 9.9% compared to the same quarter last year. As a group, equities research analysts expect that Zoetis Inc will post 3.11 EPS for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 3rd. Stockholders of record on Tuesday, November 20th will be issued a $0.126 dividend. This represents a $0.50 dividend on an annualized basis and a dividend yield of 0.54%. The ex-dividend date of this dividend is Monday, November 19th. Zoetis’s payout ratio is currently 20.83%.

WARNING: This report was first published by WKRB News and is the sole property of of WKRB News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.wkrb13.com/2018/11/15/norinchukin-bank-the-has-20-52-million-position-in-zoetis-inc-zts.html.

Zoetis Company Profile

Zoetis, Inc discovers, develops and manufactures a portfolio of animal health medicines and vaccines. Its products are complemented by diagnostic products, genetic tests, bio devices and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal. The firm provides its services though five categories namely, anti-invectives, vaccines, parasitic ides, medicated feed additives, and other pharmaceuticals.

Recommended Story: What is the quiet period?

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply